Human FABP4
Slide this table
| Cat-Nr. | 400-018 |
| Size | 25 µg |
| Price | 199 € |
| Source | E. coli |
| Label | His-Tag |
| Formulation | lyophilized |
| Purity Confirmation | > 98% by SDS-PAGE |
| Length [aa] | 140 |
| Molecular Weight | 15.7 kDa |
| N Terminal Sequence | CDAFV |
| Biological Activity | Data not available. |
| Species Reactivity | Human |
| Buffer | PBS |
| Reconstitution | Centrifuge vial prior to opening. Human FABP4 should be reconstituted in water to a concentration of 0.1 mg/ml. This solution can be diluted in water or other buffer solutions or stored at -20°C. |
| Stability and Storage | The lyophilized human FABP4, though stable at room temperature, is best stored desiccated below 0°C. Reconstituted human FABP4 should be stored in working aliquots at -20°C. |
| Synonyms | Adipocyte lipid-binding protein, Adipocyte-type fatty acid-binding protein, Fatty acid-binding protein 4, A-FABP, AFABP |
| Description | Fatty acid binding protein 4 (FABP4), also known as adipocyte P2 and A FABP (adipocyte FABP), is a FABP family member that is expressed in adipocytes and monocyte derived foam cells. It is a lipid transport protein that binds long chain fatty acid and retinoic acid. Human and mouse FABP4 share a 91% amino acid sequence homology. FABP4 plays an important role in maintaining glucose and lipid homeostasis and has been primarily regarded as an adipocyte- and macrophage-specific protein. However recent studies suggest that it may be more widely expressed. A strong FABP4 expression was found in endothelial cells (ECs) of capillaries and small veins in several mouse and human tissues, including the heart and kidney. FABP4 was also detected in the ECs of mature human placental vessels and infantile hemangiomas, the most common tumor of infancy and ECs. In most of these cases, FABP4 was detected in both the nucleus and cytoplasm. FABP4 mRNA and protein levels were significantly induced in cultured ECs by VEGF-A and bFGF treatment. The effect of VEGF-A on FABP4 expression was inhibited by chemical inhibition or short-hairpin (sh) RNA-mediated knockdown of VEGFR-2 (KDR), whereas the VEGFR1 agonists, PlGF-1 and PlGF-2, had no effect on FABP4 expression. Knockdown of FABP4 in ECs significantly reduced proliferation both under baseline conditions and in response to VEGF and bFGF. Thus, FABP4 emerged as a novel target of the VEGF/VEGFR-2 pathway and a positive regulator of cell proliferation in ECs. |
| Protein Sequence | MCDAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISVNGDVITIKSESTFKNTEISFILGQEFDEVTADDRKVKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTSTRVYERALEHHHHHH |
| Uniprot ID | P15090 |
| Protein RefSeq | NP_001433.1 |
| mRNA RefSeq | NM_001442.2 |
Figures
SDS-PAGE analysis of recombinant human FABP4. Sample was loaded in 15% SDS-polyacrylamide gel under reducing condition and stained with Coomassie blue.
All prices plus VAT + possible delivery charges